Genmab/AbbVie Lymphoma Trial Meets Main Goal, Analyst Eyes Bigger Market Opportunity

Genmab A/S – ADR (NASDAQ: GMAB ) on Monday shared topline results from the Phase 3 EPCORE DLBCL-4 trial. The trial evaluated the combination of fixed-duration epcoritamab and lenalidomide, compared to standard-of-care, rituximab plus gemcitabine plus oxaliplatin (R-GemOx), in adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who received at least one prior line of treatment. • Genmab stock is surging to new heights today. Why is GMAB stock up today? Genmab and AbbVie Inc. (NYSE: ABBV ) continue to evaluate epcoritamab as a monotherapy and in combination across lines of therapy in a range of hematologic malignancies. Read Also: Genmab Lymphoma Study Misses Key Target, Analyst Still Sees Upside Phase 3 Trial Meets Primary Progression-Free Survival Goal The trial met its primary objective, demonstrating statistically significant and clinically m...